Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial

The Lancet

Volumn 377, Issue 9779, 2011, Pages 1749-1759

  Seymour, Matthew T ^a   Thompson, Lindsay C ^b   Wasan, Harpreet S ^c   Middleton, Gary ^d   Brewster, Alison E ^e   Shepherd, Stephen F ^f   O'Mahony, M Sinead ^e   Maughan, Timothy S ^e   Parmar, Mahesh ^b   Langley, Ruth E ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; LEVOFOLINATE; OXALIPLATIN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FRAIL ELDERLY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LETHARGY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RISK FACTOR; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT INDICATION; UNITED KINGDOM; VOMITING;

EID: 79956346875     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60399-1     Document Type: Article

References (31)

1. J Ferlay, P Autier, M Boniol Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 2007 581 592 (Pubitemid 46359643)
2. American Cancer Society Cancer facts and figures, 2006 2006 American Cancer Society Atlanta http://www.cancer.org/downloads/STT/CAFF2006PWSecured.pdf (accessed April 26, 2011).
3. UK Office of National Statistics Mortality statistics. 2007 registrations http://www.statistics.gov.uk/STATBASE/Expodata/Spreadsheets/D9784.csv (accessed April 26, 2011).
4. G Folprecht, MT Seymour, L Saltz Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2691 patients in randomized controlled trials J Clin Oncol 26 2008 1443 1451
5. A De Gramont, A Figer, MT Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947 (Pubitemid 30644117)
6. JY Douillard, D Cunningham, AD Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047 (Pubitemid 30162806)
7. C Tournigand, T André, E Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
8. CA Townsley, R Selby, LL Siu Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials J Clin Oncol 23 2005 3112 3124 (Pubitemid 46224135)
9. DJ Sargent, CH Köhne, HK Sanoff Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer J Clin Oncol 27 2009 1948 1955
10. MT Seymour, TS Maughan, JA Ledermann for the FOCUS Trial Investigators and the National Cancer Research Institute Colorectal Clinical Studies Group Different strategies of sequential and combination chemotherapy for patients with poor-prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial Lancet 370 2007 143 152 (Pubitemid 47042894)
11. EM Simonsick, AW Gardner, ET Poehlman Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures Aging Clin Exp Res 12 2000 274 280
12. MC Cort, JM Guranik, ME Saline, JD Sorkin Serum albumin level and physical disability as predictors of mortality in older patients JAMA 272 1994 1035 1042
13. MF Folstein, SE Folstein, PR McHugh 'Minimental state': a practical method for grading the cognitive state of patients for the clinician J Psychiatric Res 12 1975 189 198
14. ME Charlson, P Pompei, KL Ales, CR MacKenzie A new method of classifying prognostic comorbidity in longitudinal studies J Chron Dis 40 1987 373 383 (Pubitemid 17055592)
15. F Nouri, NB Lincoln An extended activities for daily living scale for stroke patients Clin Rehab 1 1998 233 238
16. NK Aaronson, S Ahmedzai, B Bergman The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376 (Pubitemid 23073154)
17. AS Zigmond, RP Snaith The hospital anxiety and depression scale Acta Psychiatr Scand 67 1983 361 370 (Pubitemid 13098606)
18. P Kind The EuroQoL instrument: an index of health-related quality of life B Spiker Quality of life in pharmacoeconomics in clinical trials 2nd edn. 1996 Lippincott-Raven Philadelphia
19. MRC Good Research Practice 2006 Medical Research Council London http://www.mrc.ac.uk/pdf/good-research-pracice.pdf (accessed Sept 8, 2006).
20. SL Cheeseman, SP Joel, JD Chester A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer Br J Cancer 87 2002 393 399 (Pubitemid 34983562)
21. C Twelves, C Butts, J Cassidy Capecitabine in combination with oxaliplatin as first line therapy for patients with advanced or metastatic cancer: preliminary results of an international multicenter phase II study Eur J Cancer 37 suppl 6 2001 272 (1005 abstr).
22. P Therasse, SG Arbuck, EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumours J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
23. MT Seymour, ML Slevin, DJ Kerr A randomized trial assessing the addition of interferon α2a to 5-fluorouracil and leucovorin in advanced colorectal cancer J Clin Oncol 14 1996 2280 2288 (Pubitemid 26264879)
24. G Rosati, S Cordio, G Bordonaro Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study Ann Oncol 21 2010 781 786
25. R Adams, R Wilson, MT Seymour Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN) Eur J Cancer 7 suppl 3 2009 10 (15LBA abstr).
26. TS Maughan, R Adams, CG Smith Addition of cetuximab to oxaliplatin-based combination chemotherapy in patients with KRAS wild-type advanced colorectal cancer: a randomised superiority trial (MRC COIN) Eur J Cancer 7 suppl 3 2009 4 (6LBA abstr).
27. C Tournigand, T Andre, E Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2004 229 237 (Pubitemid 41095086)
28. C Twelves, M Boyer, M Findlay Capecitabine (Xeloda) improves medical resource use compared with 5FU + leucovorin in a phase III trial in patients with advanced colorectal carcinoma Eur J Cancer 37 2001 597 604 (Pubitemid 32261017)
29. HAAM Maas, MLG Janssen-Heijnen, MGMO Rikkert, ANM Wymenga Comprehensive geriatric assessment and its clinical impact in oncology Eur J Cancer 43 2007 2161 2169 (Pubitemid 47539124)
30. MW Saif, SM Lichtman Chemotherapy options and outcomes in older adult patients with colorectal cancer Crit Rev Oncol Hematol 79 2009 155 169
31. NC Tebbutt, V Gebski, K Wilson International randomized phase III study of capecitabine, bevacizumab, and mitomycin C in first-line metastatic colorectal cancer: final results of the AGITG MAX trial J Clin Oncol 27 suppl 2009 4023 (abstr).